Come join our panel of industry experts for an interactive discussion of important recent changes in patent laws and how they affect the ability of innovators to bring new treatments to patients.

Topics to be addressed will include:

• The America Invents Act (AIA) changed the US patent system from the first-to-invent to first-to-file. The “race” to file often conflicts the timing of experimental data necessary to support patent claims. What is the optimal balance?
• The Myriad, Prometheus, and Alice cases have changed the standard regarding patent-eligibility. How have these cases affected filing decisions?
• The AIA dramatically expanded opportunities for third parties to challenge already granted patents, through the US Patent Office. How do patents fare now?
• The new biosimilars law (BPCIA) incentivized generic biologics through a streamlined litigation process known as “patent dance.” Does it work?
• The US Supreme Court has issued over a dozen decisions fundamentally changing numerous aspects of the patent system. Which decisions have the biggest impact on biotech and pharma patents?
• Cases to watch in the future

Speakers:

• Karen E. Brown, PhD, JD, Vice President & Chief Intellectual Property Counsel, Ironwood Pharmaceuticals
• Jennifer Elliott, PhD, JD, Director, Intellectual Property, The Broad Institute
• Kimya Harris, PhD, Senior Director Intellectual Property, R&D, ImmunoGen, Inc.
• Hans Sauer, PhD, JD, Vice President & Deputy General Counsel for Intellectual Property, Biotechnology Innovation Organization (BIO)

Co-moderators:

• Mike Biro, PhD, JD, Senior Counsel, CRISPR Therapeutics
• Konstantin Linnik, PhD, JD, Partner, Nutter McClennen & Fish LLP